Cargando...
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
The recent approval of molecular-targeted therapies for myeloproliferative neoplasm-associated myelofibrosis (MPN-MF) has dramatically changed its therapeutic landscape. Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF,...
Gardado en:
| Publicado en: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4445786/ https://ncbi.nlm.nih.gov/pubmed/26056473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S31916 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|